Weight‑loss drug market fragments

A weight-loss market that looked like a two-company race now has three different fights happening at once: pills against pills, higher doses against standard doses, and branded drugs against cheap copies. The split showed up this week in new comparison data, a new United States approval, and a price war in India. (healio.com) (fda.gov) (cnbc.com) The first split is about format. One camp is trying to turn weight-loss treatment into a daily pill, while the older blockbuster products still rely on weekly injections. (healio.com) (jamanetwork.com) That matters because pills remove the needle, but they do not remove the tradeoff. At the Obesity Medicine Association meeting, investigators reported that semaglutide 25 milligram tablets were tied to greater mean weight loss than Eli Lilly’s orforglipron 36 milligram tablets in an indirect comparison built from separate trials, not a head-to-head study. (healio.com) (pharmacytimes.com) The gap was about 3 percentage points in favor of oral semaglutide, and the analysis also suggested higher odds that patients would stop orforglipron because of side effects, especially stomach-related side effects. Novo Nordisk presented those results from OASIS 4 and ATTAIN-1 data, so investors and doctors will still want a direct trial before treating the numbers as final. (pharmacytimes.com) (prnewswire.com) The second split is about dose. Novo Nordisk now has a newly approved 7.2 milligram version of Wegovy, called Wegovy HD, for adults with obesity or overweight plus at least one weight-related condition. (fda.gov) (ajmc.com) The Food and Drug Administration cleared that higher dose in 54 days under its National Priority Voucher pilot, which is far faster than the usual 10- to 12-month review clock. In the 72-week STEP UP trial, semaglutide 7.2 milligrams produced 20.7% mean weight loss, compared with 17.5% on the existing 2.4 milligram dose and 2.4% on placebo. (fda.gov) (pharmacytimes.com) That creates a ladder inside one brand. A patient who does not get enough benefit from 2.4 milligrams can now move up to 7.2 milligrams before a doctor starts talking about surgery or a switch to a different medicine. (ajmc.com) (jamanetwork.com) The third split is about geography and price, and India is showing it in real time. After Novo Nordisk’s semaglutide patent expired there, at least five Indian drugmakers launched cheaper versions and undercut the original price by as much as 80%. (cnbc.com) (statnews.com) That price shock is already moving share. Eli Lilly’s share of India’s weight-loss drug market fell to 56% in March from 61% in February, while Novo Nordisk held at 25% after cutting prices to defend Ozempic and Wegovy against the new generics. (finance.yahoo.com) (msn.com) So the market is no longer one simple bet on “the best obesity drug.” In the United States, the contest is turning on pill convenience and higher-dose efficacy, while in India the contest is turning on who can get close enough on effect at a price millions more people can actually pay. (healio.com) (fda.gov) (cnbc.com)